Zacks: Analysts Anticipate Ritter Pharmaceuticals Inc (RTTR) Will Announce Earnings of -$0.05 Per Share

Equities analysts expect Ritter Pharmaceuticals Inc (NASDAQ:RTTR) to post ($0.05) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Ritter Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.04) and the lowest estimate coming in at ($0.06). Ritter Pharmaceuticals reported earnings of ($0.74) per share during the same quarter last year, which suggests a positive year over year growth rate of 93.2%. The business is expected to report its next quarterly earnings report on Monday, February 26th.

On average, analysts expect that Ritter Pharmaceuticals will report full-year earnings of ($0.39) per share for the current year, with EPS estimates ranging from ($0.42) to ($0.35). For the next fiscal year, analysts forecast that the firm will post earnings of ($0.30) per share, with EPS estimates ranging from ($0.40) to ($0.20). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Ritter Pharmaceuticals.

RTTR has been the subject of a number of analyst reports. Roth Capital set a $2.00 price objective on shares of Ritter Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, October 23rd. Zacks Investment Research cut shares of Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, December 26th. HC Wainwright reduced their price objective on shares of Ritter Pharmaceuticals from $7.00 to $1.50 and set a “buy” rating for the company in a research note on Monday, October 23rd. Finally, ValuEngine upgraded shares of Ritter Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $2.10.

Shares of Ritter Pharmaceuticals (NASDAQ RTTR) opened at $0.32 on Thursday. Ritter Pharmaceuticals has a one year low of $0.27 and a one year high of $3.42. The firm has a market cap of $14.75, a price-to-earnings ratio of -0.28 and a beta of 0.53.

A hedge fund recently bought a new stake in Ritter Pharmaceuticals stock. Susquehanna International Group LLP bought a new stake in shares of Ritter Pharmaceuticals Inc (NASDAQ:RTTR) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 2,222,522 shares of the biotechnology company’s stock, valued at approximately $778,000. Susquehanna International Group LLP owned about 4.49% of Ritter Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 33.42% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Get a free copy of the Zacks research report on Ritter Pharmaceuticals (RTTR)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply